Clinical diversity and treatment results in Tegumentary Leishmaniasis: A European clinical report in 459 patients

Archive ouverte

Guery, Romain | Walker, Stephen, L. | Harms, Gundel | Neumayr, Andreas L C | van Thiel, Pieter | Gangneux, Jean-Pierre | Clerinx, Jan | Soebirk, Sara Karlsson | Visser, Leo | Lachaud, Laurence | Bailey, Mark N. | Bart, Aldert | Ravel, Christophe | van Der Auwera, Gert | Blum, Johannes | Lockwood, Diana | Buffet, Pierre

Edité par CCSD ; Public Library of Science -

International audience. Background : Cutaneous leishmaniasis (CL) is frequent in travellers and can involve oro-nasal mucosae. Clinical presentation impacts therapeutic management. Methodology - Demographic and clinical data from 459 travellers infected in 47 different countries were collected by members of the European LeishMan consortium. The infecting Leishmania species was identified in 198 patients. Principal findings : Compared to Old World CL, New World CL was more frequently ulcerative (75% vs 47%), larger (3 vs 2cm), less frequently facial (17% vs 38%) and less frequently associated with mucosal involvement (2.7% vs 5.3%). Patients with mucosal lesions were older (58 vs 30 years) and more frequently immunocompromised (37% vs 3.5%) compared to patients with only skin lesions. Young adults infected in Latin America with L. braziliensis or L. guyanensis complex typically had an ulcer of the lower limbs with mucosal involvement in 5.8% of cases. Typically, infections with L. major and L. tropica acquired in Africa or the Middle East were not associated with mucosal lesions, while infections with L. infantum, acquired in Southern Europe resulted in slowly evolving facial lesions with mucosal involvement in 22% of cases. Local or systemic treatments were used in patients with different clinical presentations but resulted in similarly high cure rates (89% vs 86%). Conclusion/significance : CL acquired in L. infantum-endemic European and Mediterranean areas displays unexpected high rates of mucosal involvement comparable to those of CL acquired in Latin America, especially in immunocompromised patients. When used as per recommendations, local therapy is associated with high cure rates.

Suggestions

Du même auteur

Surveillance of leishmaniasis cases from 15 European centres, 2014 to 2019: a retrospective analysis

Archive ouverte | van Der Auwera, Gert | CCSD

International audience. BackgroundSurveillance of human leishmaniasis in Europe is mostly limited to country-specific information from autochthonous infections in the southern part. As at the end of 2021, no integra...

Treatment outcome of imported cutaneous leishmaniasis among travelers and migrants infected with Leishmania major and Leishmania tropica: a retrospective study in European centers 2013 to 2019

Archive ouverte | Glans, Hedvig | CCSD

International audience. OBJECTIVES: Cutaneous leishmaniasis (CL) in Asia, Northern, and Sub-Saharan Africa is mainly caused by Leishmania major and Leishmania tropica. We describe and evaluate the treatment outcome ...

Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea

Archive ouverte | Guery, Romain | CCSD

International audience. BACKGROUND:Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) often requires systemic therapy. Liposomal amphotericin B (L-AmB) has a strong potential for a solid clinical benefi...

Chargement des enrichissements...